CSBR Champions Oncology Inc
962
$4.74
$0.16
(3.27%)
| Watchers | 962 |
| 52-Wk Low | $4.17 |
| 52-Wk High | $7.32 |
| Market Cap | $66.61M |
| Volume | 3,906.00 |
| 52-Wk High | $7.32 |
| 52-Wk Low | $4.17 |
Champions Oncology Third Quarter 2024 Earnings: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023)Simply Wall St • about 2 months ago
Champions Oncology ( NASDAQ:CSBR ) Third Quarter 2024 Results Key Financial Results Revenue: US$12.0m (down 5.9% from...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript...
Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M...
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...
Champions Oncology (NASDAQ:CSBR) publica su pr xima ronda de ganancias este martes, 12 de marzo. Esta es la gu a esencial de Benzinga para el informe de ganancias del tercer trimestre de Champions...
Champions Oncology (NASDAQ:CSBR) pubblicher i prossimi risultati degli utili questo marted 12 marzo. Per tutte le informazioni in merito, ecco la tua guida sulla pubblicazione degli utili di marted...
Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company's shares closed yesterday at $5.61. According to TipRanks, H...
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced...